A substantial body of evidence suggests that blockade of chemokine-chemokine receptor interaction with potent small-molecule receptor antagonists may be a promising therapeutic intervention for inflammatory and allergic disorders in humans. A number of pharmaceutical companies have disclosed patents and journals regarding chemokine receptor antagonists with their pharmacological activities. Recently, some chemokine receptor antagonists have successfully progressed to clinical trials, and preliminary results have suggested effectiveness in treating in human disorders. This section highlights some representative and promising chemokine receptor antagonists targeting inflammatory and allergic disorders, and “proof of concept” studies in inflammatory and allergic disorders in animals and humans.
Keywords: chemokine receptor, antagonist, inflammation, allergy, clinical study
Rights & PermissionsPrintExport